Summit Therapeutics Inc. SMMT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.48M | 62.76M | 62.59M | 77.63M | 103.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 214.61M | 220.50M | 195.21M | 224.93M | 234.21M |
| Operating Income | -214.61M | -220.50M | -195.21M | -224.93M | -234.21M |
| Income Before Tax | -208.39M | -215.70M | -189.42M | -219.17M | -231.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -208.39M | -215.70M | -189.42M | -219.17M | -231.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -208.39M | -215.70M | -189.42M | -219.17M | -231.79M |
| EBIT | -214.61M | -220.50M | -195.21M | -224.93M | -234.21M |
| EBITDA | -214.53M | -220.45M | -195.17M | -224.88M | -234.17M |
| EPS Basic | -0.26 | -0.28 | -0.24 | -0.29 | -0.31 |
| Normalized Basic EPS | -0.16 | -0.17 | -0.15 | -0.18 | -0.19 |
| EPS Diluted | -0.26 | -0.28 | -0.24 | -0.29 | -0.31 |
| Normalized Diluted EPS | -0.16 | -0.17 | -0.15 | -0.18 | -0.19 |
| Average Basic Shares Outstanding | 798.20M | 778.18M | 775.46M | 766.40M | 743.42M |
| Average Diluted Shares Outstanding | 798.20M | 778.18M | 775.46M | 766.40M | 743.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |